AI in Healthtech: DigiBio’s €38,000 Innovation Programme Opens Door for Five European Startups

Dublin-based AI in healthtech accelerator DigiBio announced its €38,000 Innovation Programme on March 15, 2026, marking a significant push to fund AI-driven healthcare solutions across Europe.

The clock is ticking—just eight days left until the April 30 application deadline. Five startups will be chosen to receive €7,600 each and join a cohort built to solve real medical problems using artificial intelligence. Since launching in 2020, DigiBio has backed over 20 healthtech ventures, becoming a key player in European health innovation.

DigiBio’s €38,000 Initiative Targets AI in Healthtech Diagnostics and Workflow Automation

Healthcare systems across Europe are increasingly turning to machine learning to speed up diagnostics and clear clinical bottlenecks. DigiBio is positioning this programme as a training ground for founders who get it: artificial intelligence doesn’t replace medical expertise. It amplifies it. OpenAI GPT-6: 3 Breakthrough Insights

The five selected startups will spend 10 months inside a structured immersion. They’ll work with seasoned healthtech mentors, gain access to real hospital environments, and learn how EU regulations actually govern medical AI. DigiBio doesn’t work like generic tech accelerators—it embeds fellows directly into healthcare systems so they can test AI models against real patient workflows instead of just theory. Google Unveils TPU 8t and

This matters because hospitals are increasingly skeptical of AI tools that sound good on paper but fail in practice. Wired has covered this problem extensively, documenting AI implementation failures across hospital networks. DigiBio’s hands-on approach is designed to prevent exactly that.

The programme isn’t funding “AI for AI’s sake.” DigiBio is specifically looking for founders solving concrete healthcare problems: better diagnostics, patient risk assessment, administrative tasks, or clinical decision support. This focus is crucial. Generic machine learning projects often die because they lack a clear clinical purpose. Here, founders are forced from day one to tie their AI work to measurable health outcomes.

Why This Matters Now: Regulatory Clarity and European AI Governance Shape Healthtech Investment

The EU’s AI Act is now in the enforcement phase, and it’s strict about high-risk AI in Healthtech System—especially those used in healthcare diagnostics and treatment decisions. Startups that don’t tackle this early often face expensive rewrites or get shut out of markets. DigiBio’s mentors include regulatory experts who walk fellows through CE marking, clinical validation, and data governance frameworks built specifically for the EU.